Correction to: Promoter hypomethylation mediated upregulation of MicroRNA-10b-3p targets FOXO3 to promote the progression of esophageal squamous cell carcinoma (ESCC)
verfasst von:
Yi-fang Lu, Jia-rui Yu, Zhao Yang, Guan-xia Zhu, Peng Gao, Huan Wang, Si-yuan Chen, Jie Zhang, Mei-yue Liu, Yi Niu, Xiao-mei Wei, Wei Wang, Feng-jin Ye, Li-xin Zhang, Yue Zhao, Guo-gui Sun
In the original publication of this manuscript [1], Fig. 6 contains a repeated image in error (the left image of ‘Migration’ and the left image of ‘Invasion’). The misused pictures do not influence the data statistics; all of the original results remain unchanged. The revised Fig. 6 is shown below:
Fig. 6
A rescue assay was further performed to confirm that FOXO3 was the functional target of miR-10b-3p. a-b The mRNA and protein levels of FOXO3 in KYSE150 and KYSE450 cell lines cotransfected with miR-10b-3p mimic and pEGFP-C1 plasmid containing FOXO3 CDS sequence. c The cell growth curve was measured by MTS cotransfected with miR-10b-3p mimic and FOXO3 plasmids in KYSE 150 cell lines, and the OD 570 was normalized to the star point (0 h). d Transwell assay of cells cotransfected with miR-10b-3p mimic and FOXO3 plasmids. e The expression of FOXO3 at the mRNA and protein level post siRNA silencing in KYSE150 cells. f Representative images and quantification of transwell assay after the transfection of FOXO3 siRNA into the KYSE150 cell lines. Each experiment was performed in triplicate. Data are presented as the mean value ± SD. ●, P < 0.05; ●●, P < 0.01
×
The authors sincerely apologize for the inconvenience caused to the readers.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Correction to: Promoter hypomethylation mediated upregulation of MicroRNA-10b-3p targets FOXO3 to promote the progression of esophageal squamous cell carcinoma (ESCC)
verfasst von
Yi-fang Lu Jia-rui Yu Zhao Yang Guan-xia Zhu Peng Gao Huan Wang Si-yuan Chen Jie Zhang Mei-yue Liu Yi Niu Xiao-mei Wei Wei Wang Feng-jin Ye Li-xin Zhang Yue Zhao Guo-gui Sun
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
